Login to Your Account

Aurinia rebounds after AURA-LV hits secondary lupus nephritis endpoints

By Marie Powers
News Editor

Friday, September 30, 2016

Investors in Aurinia Pharmaceuticals Inc. breathed a sigh of relief, and moved shares higher, after learning that both study doses in the phase IIb AURA-LV study of lupus nephritis candidate, voclosporin, met 24-week pre-specified secondary endpoints compared to control.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription